Student Loan Sudden...
Health Care: Drugs
Vanda Pharmaceuticals Inc. (VNDA: NASDAQ)
$8.51 -2.41 | -22.07%
06/19/13 - 04:00 PM ET
8.61M / 774.20K
Vol / Avg. Vol:9.16 / 10.92
Open / Prev. Close:8.20 - 9.98
Today's Range:2.92 - 13.30
52 Wk Range:203.51%
Performance YTD:TheStreet Rating:
Portfolios with VNDA
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 15
- ContributorHot Biotech Stocks Traded b...
- ContributorBreakout Stocks Of The Week...
- UserWatching
- Contributor10 Unloved Stocks to Rise U...
- Contributor10 Companies That Missed Ea...
- UserJim Luterek Portfolio 1
- Userjph1020 Portfolio 1
- UserHot Biotech Stocks
- Userbigboyjohno Portfolio 1
Latest VNDA Headlines from TheStreet
- Stock Futures Waver as Investors Go On Bernanke-Watch 06.19.13 | 09:06 am
- Vanda's Sleep Disorder Drug Is A Nightmare 06.19.13 | 07:06 am
- Commit To Purchase Vanda Pharmaceuticals At $7, Earn 21.1% Annualized 06.06.13 | 01:06 pm
- Biotech Stock Mailbag: Amarin 04.23.12 | 07:04 am
- Vanda Pharmaceuticals Inc. Stock Downgraded (VNDA) 11.08.11 | 05:11 am
- Biotech Stock Mailbag: Exelixis 10.28.11 | 06:10 am
- 5 Stocks Setting Up to Break Out 04.18.11 | 07:04 am
- Biotech Stock Mailbag: Bio-Hazards 03.25.11 | 07:03 am
- Vanda Pharmaceuticals Inc. Stock Upgraded By TheStreet Ratings (VNDA) 02.11.11 | 05:02 pm
- Vanda's Fanapt Falls Flat 02.04.11 | 11:02 am
Press Releases for VNDA
- Vanda Pharmaceuticals To Announce First Quarter 2013 Financial Results On May 9, 2013 - PR Newswire 04.18.13 | 07:04 am
- Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer - PR Newswire 04.17.13 | 07:04 pm
- Vanda Pharmaceuticals To Present At The BioCentury Future Leaders In The Biotech Industry Conference - PR Newswire 04.04.13 | 07:04 pm
- Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind - PR Newswire 03.25.13 | 06:03 am
- Vanda Withdraws Its Marketing Authorization Application For Fanaptumâ¿¢ In The European Union - PR Newswire 03.14.13 | 04:03 pm
- Vanda Pharmaceuticals To Present At The Cowen And Company 33rd Annual Health Care Conference - PR Newswire 02.27.13 | 08:02 pm
- Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint - PR Newswire 01.31.13 | 06:01 am
- Vanda Pharmaceuticals To Announce Fourth Quarter 2012 Financial Results On February 12, 2013 - PR Newswire 01.22.13 | 06:01 am
- Vanda Receives Negative Opinion From CHMP On Fanaptumâ¿¢ For The Treatment Of Schizophrenia - PR Newswire 12.13.12 | 08:12 pm
- Vanda Pharmaceuticals To Present At The Lazard Healthcare Conference - PR Newswire 11.05.12 | 07:11 pm
Partner Headlines for VNDA
- Morning Market Movers - Benzinga 05.17.13 | 09:05 am
- Vanda Pharmaceuticals Earnings: Here’s Why Shares are Up Now - Wall St. Cheat Sheet 05.09.13 | 11:05 am
- Stock Watch Wednesday, 19 December - Seeking Alpha 12.19.12 | 09:12 am
- Cashed Up Biotech Vanda Could Keep On Falling - Seeking Alpha 09.05.12 | 09:09 am
- 4 Cash Loaded Biotech Stocks With Little Debt - Seeking Alpha 08.30.12 | 09:08 am
- Healthcare Stocks To Watch This Week - Seeking Alpha 10.12.11 | 08:10 am
- 6 Deeply Undervalued Biotech Stocks - Seeking Alpha 07.27.11 | 09:07 am
- What FDA's Delay of Probuphine Trial Means for Titan Pharmaceuticals - Seeking Alpha 06.20.11 | 08:06 am
- As the Market Dips, It's Time to Look for Biotech Sector Deals - Seeking Alpha 06.12.11 | 09:06 am
- Titan Pharmaceuticals: $2 Mark Broken - Looks to Hold - Seeking Alpha 05.26.11 | 09:05 am
